Advances in Treatment of Bladder Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 908
Special Issue Editors
Interests: urolithiasis; ureterorenoscopy; percutaneous nephrolithotomy; bladder cancer; radical cystectomy; transurethral resection; TURBT; prostate cancer; renal cancer
Interests: urologic surgery; laparoscopic surgery; robotic urologic surgery; urogenital trauma; genitourinary surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Collection explores the latest breakthroughs in bladder cancer research, diagnosis, and treatment. With bladder cancer presenting unique clinical challenges, the need for innovative approaches has never been more pressing. This collection welcomes contributions that shed light on the evolving biological, molecular, and clinical landscape of bladder cancer, offering insights that promise to revolutionize patient care.
Aims and Scope
Bladder cancer remains one of the most prevalent malignancies affecting the urinary tract, and its management is rapidly advancing through novel diagnostic tools and therapeutic strategies. This Special Collection aims to highlight pioneering research that includes, but is not limited to, the following focal areas:
Novel Diagnostic Biomarkers: Studies unveiling new biomarkers that enable earlier detection, more precise diagnoses, and improved stratification of bladder cancer subtypes.
Innovative Therapeutic Approaches: Research on targeted therapies, advancements in surgery, immunotherapy or chemotherapy, and personalized treatment regimens that address the heterogeneity of bladder cancer.
Molecular Mechanisms and Genomics: Investigations into the genetic and molecular underpinnings of bladder cancer, elucidating pathways that drive tumor development and progression.
Integration of Multi-Omics Data: Articles that integrate genomics, transcriptomics, proteomics, and other -omics technologies to develop comprehensive profiles of bladder cancer, paving the way for precision medicine.
Significance and Future Directions
Advances in bladder cancer research are poised to transform clinical practice by enabling earlier diagnosis, improving prognostic accuracy, and tailoring treatments to individual patients. The integration of novel biomarkers and multi-omics strategies holds promise not only for enhanced therapeutic efficacy but also for minimizing adverse effects. As our understanding of the disease deepens, this collection will serve as a platform to discuss innovative approaches that bridge the gap between bench research and bedside application.
By supporting this collection, the journal reinforces its commitment to SDG 3 (Good Health and Well-being) and the advancement of clinical practice in oncology. All manuscripts will undergo a rigorous peer review process in line with our editorial policies, ensuring the integrity and quality of the published research. We invite researchers, clinicians, and allied professionals to contribute their original work and reviews, helping to shape the future landscape of bladder cancer management.
We look forward to receiving your submissions and to fostering a rich dialogue on the cutting-edge developments in bladder cancer research and treatment.
Dr. Murat Akand
Dr. Guglielmo Mantica
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- diagnostic biomarkers
- genomics
- therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
